A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors.
Latest Information Update: 09 Nov 2022
At a glance
- Drugs RGT 100 (Primary) ; RGT 100 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Merck Sharp & Dohme; Rigontec
- 22 May 2019 This trial has been completed in France, according to the European Clinical Trials Database record.
- 02 Feb 2019 This trial has been completed in United Kingdom, according to the European Clinical Trials Database record.
- 25 Oct 2018 According to a Merck media release, data from the study were presented at ESMO 2018.